Skip to main content
SpringerLink
Log in

Neurobiology of α-synuclein

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

α-Synuclein is an abundant neuronal protein that has been linked both to normal synaptic function and to neurodegeneration. Most significantly, mutations in the gene encoding for α-synuclein are responsible for Parkinson’s disease (PD) in rare familial cases, and the aggregated protein is a major component of Lewy bodies found in sporadic PD. Here we review recent data regarding the structure, the regulation at the transcriptional and posttranslational level, and the physiologic and aberrant functions of α-synuclein. We focus in particular on the fibrilization potential of α-synuclein and on its link with defects in protein degradation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., et al. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 11,282–11,286.

    CAS  Google Scholar 

  2. Jakes R., Spillantini M.G., and Goedert M. (1994) Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27–32.

    PubMed  CAS  Google Scholar 

  3. Maroteaux L., Campanelli J.T., and Scheller R.H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804–2815.

    PubMed  CAS  Google Scholar 

  4. George J.M., Jin H., Woods W.S., and Clayton D.F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361–372.

    PubMed  CAS  Google Scholar 

  5. Bayer T.A., Jakala P., Hartmann T., Havas L., McLean C., Culvenor J.G., et al. (1999) Alphasynuclein accumulates in Lewy bodies in Parkinson’s disease and dementia with Lewy bodies but not in Alzheimer’s disease beta-amyloid plaque cores. Neurosci. Lett. 266, 213–216.

    PubMed  CAS  Google Scholar 

  6. Culvenor J.G., McLean C.A., Cutt S., Campbell B.C., Maher F., Jakala P., et al. (1999) Non-Abeta component of Alzheimer’s disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am. J. Pathol. 155, 1173–1181.

    PubMed  CAS  Google Scholar 

  7. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. (1997) Mutation in the alpha-synuclein identified in families with Parkinson’s disease. Science 276, 2045–2047.

    PubMed  CAS  Google Scholar 

  8. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839–840.

    PubMed  CAS  Google Scholar 

  9. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. (1998) Alphasynuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469–6473.

    PubMed  CAS  Google Scholar 

  10. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., et al. (1998) Aggragation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879–884.

    PubMed  CAS  Google Scholar 

  11. Duda J.E., Lee V.M., and Trojanowski J.Q. (2000) Neuropathology of synuclein aggregates. J. Neurosci. Res. 61, 121–127.

    PubMed  CAS  Google Scholar 

  12. Dickson D.W. (2001) Alpha-synuclein and the Lewy body disorders. Curr. Opin. Neurol. 14, 423–432.

    PubMed  CAS  Google Scholar 

  13. Lynch T., Farrer M., Hutton M., and Hardy J. (1997) Genetics of Parkinson’s disease. Science 278, 1212–1213.

    PubMed  CAS  Google Scholar 

  14. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 18, 106–108.

    PubMed  CAS  Google Scholar 

  15. Bostantjopoulou S., Katsarou Z., Papadimitriou A., Veletza V., Hatzigeorgiou G., and Lees A. (2001) Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov. Disord. 16, 1007–1013.

    PubMed  CAS  Google Scholar 

  16. Papapetropoulos S., Paschalis C., Athanassiadou A., Papadimitriou A., Ellul J., Polymeropoulos M.H., et al. (2001) Clinical phenotype in patients with alpha-synuclein Parkinson’s disease living in Greece in comparison with patients with sporadic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 70, 662–665.

    PubMed  CAS  Google Scholar 

  17. Spira P.J., Sharpe D.M., Halliday G., Cavanagh J., and Nicholson G.A. (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alphasynuclein mutation. Ann. Neurol. 49, 313–319.

    PubMed  CAS  Google Scholar 

  18. Farrer M., Maraganore D.M., Lockhart P., Singleton A., Lesnick T.G., de Andrade M., et al. (2001) Alpha-synuclein gene haplotypes are associated with Parkinson’s disease. Hum. Mol. Genet. 10, 1847–1851.

    PubMed  CAS  Google Scholar 

  19. Kruger R., Vieira-Saecker A.M., Kuhn W., Berg D., Muller T., Kuhnl N., et al. (1999) Increased susceptibility to sporadic Parkinson’s disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann. Neurol. 45, 611–617.

    PubMed  CAS  Google Scholar 

  20. Tan E.K., Matsuura T., Nagamitsu S., Khajavi M., Jankovic J., and Ashizawa T. (2000) Polymorphism of NACP-Rep1 in Parkinson’s disease: an etiologic link with essential tremor? Neurology 54, 1195–1198.

    PubMed  CAS  Google Scholar 

  21. Chiba-Falek O. and Nussbaum R.L. (2001) Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet. 10, 3101–3109.

    PubMed  CAS  Google Scholar 

  22. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. (2003) Alphasynuclein locus triplication causes Parkinson’s disease. Science 302, 841.

    PubMed  CAS  Google Scholar 

  23. Maroteaux L. and Scheller R. H. (1991) The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res. Mol. Brain Res. 11, 335–343.

    PubMed  CAS  Google Scholar 

  24. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., and Lansbury P.T. Jr. (1996) NACP, A protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35, 13,709–13,715.

    CAS  Google Scholar 

  25. Han H., Weinreb P.H., and Lansbury P.T. Jr. (1995) The core Alzheimer’s peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem. Biol. 2, 163–169.

    PubMed  CAS  Google Scholar 

  26. Conway K.A., Harper J.D., and Lansbury P.T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318–1320.

    PubMed  CAS  Google Scholar 

  27. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., et al. (1995) The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467–475.

    PubMed  CAS  Google Scholar 

  28. Giasson B.I., Uryu K., Trojanowski J.Q., and Lee V.M. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619–7622.

    PubMed  CAS  Google Scholar 

  29. Perrin R.J., Woods W.S., Clayton D.F., and George J.M. (2000) Interaction of human alpha-Synuclein and Parkinson’s disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 275, 34,393–34,398.

    CAS  Google Scholar 

  30. Jo E., Fuller N., Rand R.P., St. George-Hyslop P., and Fraser P.E. (2002) Defective membrane interactions of familial Parkinson’s. J. Mol. Biol. 315, 799–807.

    PubMed  CAS  Google Scholar 

  31. George J.M. (2002) The synucleins. Genome Biol. 3, REVIEWS3002.

  32. Uversky V.N., Gillespie J.R., and Fink A.L. (2000) Why are “natively unfolded” proteins unstructured under physiologic conditions? Proteins 41, 415–427.

    PubMed  CAS  Google Scholar 

  33. Kim J. (1997) Evidence that the precursor protein of non-A beta component of Alzheimer’s disease amyloid (NACP) has an extended structure primarily composed of random-coil. Mol. Cells 7, 78–83.

    PubMed  CAS  Google Scholar 

  34. Giasson B.I., Murray I.V., Trojanowski J.Q., and Lee V.M. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alphasynuclein is essential for filament assembly. J. Biol. Chem. 276, 2380–2386.

    PubMed  CAS  Google Scholar 

  35. Miake H., Mizusawa H., Iwatsubo T., and Hasegawa M. (2002) Biochemical characterization of the core structure of alpha-synuclein filaments. J. Biol. Chem. 277, 19,213–19,219.

    CAS  Google Scholar 

  36. Der-Sarkissian A., Jao C.C., Chen J., and Langen R. (2003) Structural organization of alphasynuclein fibrils studied by site-directed spin labeling. J. Biol. Chem. 278, 37,530–37,535.

    CAS  Google Scholar 

  37. Murray I.V., Giasson B.I., Quinn S.M., Koppaka V., Axelsen P.H., Ischiropoulos H., et al. (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42, 8530–8540.

    PubMed  CAS  Google Scholar 

  38. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., and Wolozin B. (2000) The A53T alpha-synuclein mutation increases irondependent aggregation and toxicity. J. Neurosci. 20, 6048–6054.

    PubMed  CAS  Google Scholar 

  39. Paxinou E., Chen Q., Weisse M., Giasson B.I., Norris E.H., Rueter S.M., et al. (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21, 8053–8061.

    PubMed  CAS  Google Scholar 

  40. Hashimoto M. and Masliah E. (1999) Alphasynuclein in Lewy body disease and Alzheimer’s disease. Brain Pathol. 9, 707–720.

    PubMed  CAS  Google Scholar 

  41. Souza J.M., Giasson B.I., Chen Q., Lee V.M., and Ischiropoulos H. (2000) Dityrosine cross-linking promotes formation of stable alpha — synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 18,344–18,349.

    CAS  Google Scholar 

  42. Takahashi T., Yamashita H., Nakamura T., Nagano Y., and Nakamura S. (2002) Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res. 938, 73–80.

    PubMed  CAS  Google Scholar 

  43. Norris E.H., Giasson B.I., Ischiropoulos H., and Lee V.M. (2003) Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J. Biol. Chem. 278, 27,230–27,240.

    CAS  Google Scholar 

  44. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985–989.

    PubMed  CAS  Google Scholar 

  45. Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldatti R., Vukosavic S., et al. (2001) Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease. J. Neurochem. 76, 637–640.

    PubMed  CAS  Google Scholar 

  46. Uversky V.N., Li J., and Fink A.L. (2001) Pesticides directly accelerate the rate of alphasynuclein fibril formation: a possible factor in Parkinson’s disease. FEBS Lett. 500, 105–108.

    PubMed  CAS  Google Scholar 

  47. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., and Di Monte D.A. (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277, 1641–1644.

    PubMed  CAS  Google Scholar 

  48. Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., et al. (2000) Constitutive phosphorylation of the Parkinson’s disease associated alpha-synuclein. J. Biol. Chem. 275, 390–397.

    PubMed  CAS  Google Scholar 

  49. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., et al. (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160–164.

    PubMed  CAS  Google Scholar 

  50. Pronin A.N., Morris A.J., Surguchov A., and Benovic J.L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26,515–26,522.

    CAS  Google Scholar 

  51. Ellis C.E., Schwartzberg P.L., Grider T.L., Fink D.W., and Nussbaum R.L. (2001) Alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J. Biol. Chem. 276, 3879–3884.

    PubMed  CAS  Google Scholar 

  52. Nakamura T., Yamashita H., Takahashi T., and Nakamura S. (2001) Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem. Biophys. Res. Commun. 280, 1085–1092.

    PubMed  CAS  Google Scholar 

  53. Nakamura T., Yamashita H., Nagano Y., Takahashi T., Avraham S., Avraham H., et al. (2002) Activation of Pyk2/RAFTK induces tyrosine phosphorylation of alpha-synuclein via Src-family kinases. FEBS Lett. 521, 190–194.

    PubMed  CAS  Google Scholar 

  54. Negro A., Brunati A.M., Donella-Deana A., Massimino M.L., and Pinna L.A. (2002) Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J. 16, 210–212.

    PubMed  CAS  Google Scholar 

  55. Clayton D.F. and George J.M. (1998) The synucleins: a family of proteins involved in synaptic function plasticity neurodegeneration and disease. Trends Neurosci. 21, 249–254.

    PubMed  CAS  Google Scholar 

  56. Clayton D.F. and George J.M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120–129.

    PubMed  CAS  Google Scholar 

  57. Giasson B.I., Duda J.E., Forman M.S., Lee V.M., and Trojanowski J.Q. (2001) Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons. Exp. Neurol. 172, 354–362.

    PubMed  CAS  Google Scholar 

  58. Mori F., Tanji K., Yoshimoto M., Takahashi H., and Wakabayashi K. (2002) Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp. Neurol. 176, 98–104.

    PubMed  CAS  Google Scholar 

  59. Hashimoto M., Yoshimoto M., Sisk A., Hsu L.J., Sundsmo M., Kittel A., et al. (1997) NACP a synaptic protein involved in Alzheimer’s disease, is differentially regulated during megakaryocyte differentiation. Biochem. Biophys. Res. Commun. 237, 611–616.

    PubMed  CAS  Google Scholar 

  60. Park S.M., Jung H.Y., Kim H.O., Rhim H., Paik S.R., Chung K.C., et al. (2002) Evidence that alpha-synuclein functions as a negative regulator of Ca(++)-dependent alpha-granule release from human platelets. Blood 100, 2506–2514.

    PubMed  CAS  Google Scholar 

  61. Tompkins M.M., Gai W.P., Douglas S., and Bunn S.J. (2003) Alpha-synuclein expression localizes to the Golgi apparatus in bovine adrenal medullary chromaffin cells. Brain Res. 984, 233–236.

    PubMed  CAS  Google Scholar 

  62. Hsu L.J., Mallory M., Xia Y., Veinbergs I., Hashimoto M., Yoshimoto M., et al. (1998) Expression pattern of synucleins (non-Abeta component of Alzheimer’s disease amyloid precursor protein/alpha-synuclein) during murine brain development. J. Neurochem. 71, 338–344.

    PubMed  CAS  Google Scholar 

  63. Stefanis L., Larsen K.E., Rideout H.J., Sulzer D., and Greene L.A. (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitindependent degradation system loss of dopamine release and autophagic cell death. J. Neurosci. 21, 9549–9560.

    PubMed  CAS  Google Scholar 

  64. Rideout H.J., Dietrich P., Savalle M., Dauer W.T., and Stefanis L. (2003) Regulation of alpha-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons. J. Neurochem. 84, 803–813.

    PubMed  CAS  Google Scholar 

  65. Mori F., Tanji K., Yoshimoto M., Takahashi H., and Wakabayashi K. (2002) Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system. Brain Res. 941, 118–126.

    PubMed  CAS  Google Scholar 

  66. Goers J., Manning-Bog A.B., McCormack A.L., Millett I.S., Doniach S., Di Monte D.A., et al. (2003) Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42, 8465–8471.

    PubMed  CAS  Google Scholar 

  67. Davidson W.S., Jonas A., Clayton D.F., and George J.M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443–9449.

    PubMed  CAS  Google Scholar 

  68. Perrin R.J., Woods W.S., Clayton D.F., and George J.M. (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 276, 41,958–41,962.

    CAS  Google Scholar 

  69. Cole N.B., Murphy D.D., Grider T., Rueter S., Brasaemle D., and Nussbaum R.L. (2002) Lipid droplet binding and oligomerization properties of the Parkinson’s disease protein alpha-synuclein. J. Biol. Chem. 277, 6344–6352.

    PubMed  CAS  Google Scholar 

  70. Sharon R., Goldberg M.S., Bar-Josef I., Betensky R.A., Shen J., and Selkoe D.J. (2001) Alpha-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acidbinding proteins. Proc. Natl. Acad. Sci. USA 98, 9110–9115.

    PubMed  CAS  Google Scholar 

  71. Lee M., Hyun D., Halliwell B., and Jenner P. (2001) Effect of the overexpression of wildtype or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76, 998–1009.

    PubMed  CAS  Google Scholar 

  72. Jo E., McLaurin J., Yip C.M., St George-Hyslop P., and Fraser P.E. (2000) Alpha-synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275, 34,328–34,334.

    CAS  Google Scholar 

  73. Zhu M. and Fink A.L. (2003) Lipid binding inhibits alpha-synuclein fibril formation. J. Biol. Chem. 278, 16,873–16,877.

    CAS  Google Scholar 

  74. Withers G.S., George J.M., Banker G.A., and Clayton D.F. (1997) Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res. Dev. Brain Res. 99, 87–94.

    PubMed  CAS  Google Scholar 

  75. Murphy D.D., Rueter S.M., Trojanowski J.Q., and Lee V.M. (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214–3220.

    PubMed  CAS  Google Scholar 

  76. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239–252.

    PubMed  CAS  Google Scholar 

  77. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., Mcllwain K.L., et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22, 8797–8807.

    PubMed  CAS  Google Scholar 

  78. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., et al. (1999) Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 5782–5791.

    PubMed  CAS  Google Scholar 

  79. Jenco J.M., Rawlingson A., Daniels B., and Morris A.J. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and betasynucleins. Biochemistry 37, 4901–4909.

    PubMed  CAS  Google Scholar 

  80. Jensen P.H., Hager H., Nielsen M.S., Hojrup P., Gliemann J., and Jakes R. (1999) Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274, 25,481–25,489.

    CAS  Google Scholar 

  81. Engelender S., Kaminsky Z., Guo X., Sharp A.H., Amaravi R.K., Kleiderlein J.J., et al. (1999) Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22, 110–114.

    PubMed  CAS  Google Scholar 

  82. Martinez J., Moeller I., Erdjument-Bromage H., Tempst P., and Lauring B. (2003) Parkinson’s disease-associated alpha-synuclein is a calmodulin substrate. J. Biol. Chem. 278, 17,379–17,387.

    CAS  Google Scholar 

  83. Kim T.D., Paik S.R., and Yang C.H. (2002) Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry 41, 13,782–13,790.

    CAS  Google Scholar 

  84. Souza J.M., Giasson B.I., Lee V.M., and Ischiropoulos H. (2000) Chaperone-like activity of synucleins. FEBS Lett. 474, 116–119.

    PubMed  CAS  Google Scholar 

  85. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., and Zigmond M.J. (2002) A role for alphasynuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090–3099.

    PubMed  CAS  Google Scholar 

  86. Lee F.J., Liu F., Pristupa Z.B., and Niznik H.B. (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916–926.

    PubMed  CAS  Google Scholar 

  87. Wersinger C. and Sidhu A. (2003) Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett. 340, 189–192.

    PubMed  CAS  Google Scholar 

  88. Wersinger C., Prou D., Vernier P., and Sidhu A. (2003) Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 17, 2151–2153.

    PubMed  CAS  Google Scholar 

  89. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., et al. (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 99, 14,524–14,529.

    CAS  Google Scholar 

  90. da Costa C.A., Ancolio K., and Checler F. (2000) Wild-type but not Parkinson’s disease-related ala-53 → Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem. 275, 24,065–24,069.

    Google Scholar 

  91. Seo J.H., Rah J.C., Choi S.H., Shin J.K., Min K., Kim H.S., et al. (2002) Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 16, 1826–1828.

    PubMed  CAS  Google Scholar 

  92. Hashimoto M., Hsu L.J., Rockenstein E., Takenouchi T., Mallory M., and Masliah E. (2002) Alpha-synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J. Biol. Chem. 277, 11,465–11,472.

    CAS  Google Scholar 

  93. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., and Lansbury T. Jr. (2000) Acceleration of oligomerization not fibrillization is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571–576.

    PubMed  CAS  Google Scholar 

  94. Goldberg M.S. and Lansbury P.T. Jr. (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson’s disease? Nat. Cell Biol. 2, E115–119.

    PubMed  CAS  Google Scholar 

  95. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury P.T. Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346–1349.

    PubMed  CAS  Google Scholar 

  96. Volles M.J. and Lansbury P.T. Jr. (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson’s disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595–4602.

    PubMed  CAS  Google Scholar 

  97. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury P.T. Jr. (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.

    PubMed  CAS  Google Scholar 

  98. Zhou W., Schaack J., Zawada W.M., and Freed C.R. (2002) Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 926, 42–50.

    PubMed  CAS  Google Scholar 

  99. Saha A.R., Ninkina N.N., Hanger D.P., Anderton B.H., Davies A.M., and Buchman V.L. (2000) Induction of neuronal death by alpha-synuclein. Eur. J. Neurosci. 12, 3073–3077.

    PubMed  CAS  Google Scholar 

  100. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., et al. (2000) Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401–410.

    PubMed  CAS  Google Scholar 

  101. Zhou W., Hurlbert M.S., Schaack J., Prasad K.N., and Freed C.R. (2000) Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866, 33–43.

    PubMed  CAS  Google Scholar 

  102. Petrucelli L., O’Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., et al. (2002) Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007–1019.

    PubMed  CAS  Google Scholar 

  103. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., et al. (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondrial-dependent apoptosis. Hum. Mol. Genet. 10, 919–926.

    PubMed  CAS  Google Scholar 

  104. Ko L., Mehta N.D., Farrer M., Easson C., Hussey J., Yen S., et al. (2000) Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. J. Neurochem. 75, 2546–2554.

    PubMed  CAS  Google Scholar 

  105. Junn E. and Mouradian M.M. (2002) Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320, 146–150.

    PubMed  CAS  Google Scholar 

  106. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., et al. (2000) Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 9, 2683–2689.

    PubMed  CAS  Google Scholar 

  107. Xu J., Kao S.Y., Lee F.J., Song W, Jin L.W., and Yankner B.A. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600–606.

    PubMed  CAS  Google Scholar 

  108. Lee H.J. and Lee S.J. (2002) Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277, 48,976–48,983.

    CAS  Google Scholar 

  109. Gosavi N., Lee H.J., Lee J.S., Patel S., and Lee S.J. (2002) Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277, 48,984–48,992.

    CAS  Google Scholar 

  110. Lee H.J., Choi C., and Lee S.J. (2002) Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671–678.

    PubMed  CAS  Google Scholar 

  111. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H.K., and Brundin P. (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277, 38,884–38,894.

    CAS  Google Scholar 

  112. McNaught K.S., Olanow C.W., Halliwell B., Isacson O., and Jenner P. (2001) Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat. Rev. Neurosci. 2, 589–594.

    PubMed  CAS  Google Scholar 

  113. McNaught K.S., Belizaire R., Jenner P., Olanow C.W., and Isacson O. (2002) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci. Lett. 326, 155–158.

    PubMed  CAS  Google Scholar 

  114. McNaught K.S. and Jenner P. (2001) Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci. Lett. 297, 191–194.

    PubMed  CAS  Google Scholar 

  115. Rideout H.J., Larsen K.E., Sulzer D., and Stefanis L. (2001) Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78, 899–908.

    PubMed  CAS  Google Scholar 

  116. Rideout H.J. and Stefanis L. (2002) Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol. Cell. Neurosci. 21, 223–238.

    PubMed  CAS  Google Scholar 

  117. McNaught K.S., Bjorklund L.M., Belizaire R., Isacson O., Jenner P., and Olanow C.W. (2002) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13, 1437–1441.

    PubMed  CAS  Google Scholar 

  118. McNaught K.S., Mytilineou C., Jnobaptiste R., Yabut J., Shashidharan P., Jennert P., et al. (2002) Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neuroschem. 81, 301–306.

    CAS  Google Scholar 

  119. Bence N.F., Sampat R.M., and Kopito R.R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552–1555.

    PubMed  CAS  Google Scholar 

  120. Ghee M., Fournier A., and Mallet J. (2000) Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J. Neurochem. 75, 2221–2224.

    PubMed  CAS  Google Scholar 

  121. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., and Wolozin B. (2003) Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278, 11,753–11,759.

    CAS  Google Scholar 

  122. Iwata A., Miura S., Kanazawa I., Sawada M., and Nukina N. (2001) Alpha-synuclein forms a complex with transcription factor Elk-1. J. Neurochem. 77, 239–252.

    PubMed  CAS  Google Scholar 

  123. Iwata A., Maruyama M., Kanazawa I., and Nukina N. (2001) Alpha-synuclein affects the MAPK pathway and accelerates cell death. J. Biol. Chem. 276, 45,320–45,329.

    CAS  Google Scholar 

  124. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., et al. (2000) Dopaminengic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265–1269.

    PubMed  CAS  Google Scholar 

  125. Hashimoto M., Rockenstein E., and Masliah E. (2003) Transgenic models of alpha-synuclein pathology: past, present, and future. Ann. NY Acad. Sci. 991, 171–188.

    PubMed  CAS  Google Scholar 

  126. van der Putten H., Wiederhold K. H., Probst A., Barbieri S., Mistl C., Danner S., et al. (2000) Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20, 6021–6029.

    PubMed  Google Scholar 

  127. Kahle P.J., Neumann M., Ozmen L., Muller V., Odoy S., Okamoto N., et al. (2001) Selective insolubility of alpha-synuclein in human Lewy body disease is recapitulated in a transgenic mouse model. Am. J. Pathol. 159, 2215–2225.

    PubMed  CAS  Google Scholar 

  128. Neumann M., Kahl P.J., Giasson B.I., Ozmen L., Borroni E., Spooren W., et al. (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110, 1429–1439.

    PubMed  CAS  Google Scholar 

  129. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., and Lee V.M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521–533.

    PubMed  CAS  Google Scholar 

  130. Gomez-Isla T., Irizarry M.C., Mariash A., Cheung B., Soto O., Schrump S., et al. (2003) Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging 24, 245–258.

    PubMed  CAS  Google Scholar 

  131. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., et al. (2001) Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8, 535–539.

    PubMed  CAS  Google Scholar 

  132. Rathke-Hartlieb S., Kahle P.J., Neumann M., Ozmen L., Haid S., Okochi M., et al. (2001) Sensitivity to MPTP is not increased in Parkinson’s disease-associated mutant alpha-synuclein transgenic mice. J. Neurochem. 77, 1181–1184.

    PubMed  CAS  Google Scholar 

  133. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., et al. (2002) Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175, 35–48.

    PubMed  CAS  Google Scholar 

  134. Rochet J.C., Conway K.A., and Lansbury P.T. Jr. (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 39, 10,619–10,626.

    CAS  Google Scholar 

  135. Hashimoto M., Rockenstein E., Mante M., Mallory M., and Masliah E. (2001) Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213–223.

    PubMed  CAS  Google Scholar 

  136. Uversky V.N., E, M.C., Bower K.S., Li J., and Fink A.L. (2002) Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett. 515, 99–103.

    PubMed  CAS  Google Scholar 

  137. Park J.Y. and Lansbury P.T. Jr. (2003) Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic stragegy against Parkinson’s disease. Biochemistry 42, 3696–3700.

    PubMed  CAS  Google Scholar 

  138. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 3, 1301–1306.

    PubMed  CAS  Google Scholar 

  139. McCormack A.L. and Di Monte D.A. (2003) Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J. Neurochem. 85, 82–86.

    PubMed  CAS  Google Scholar 

  140. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., and Ferrante R.J. (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211–213.

    PubMed  CAS  Google Scholar 

  141. Lo Bianoc C., Ridet J.L., Schneider B.L., Deglon N., and Aebischer P. (2002) Alphasynucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc. Natl. Acad. Sci. USA 99, 10,813–10,818.

    Google Scholar 

  142. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., et al. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780–2791.

    PubMed  CAS  Google Scholar 

  143. Klein R.L., King M.A., Hamby M.E., and Meyer E.M. (2002) Dopaminergic cell loss induced by human A30P alpha-sunuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13, 605–612.

    PubMed  CAS  Google Scholar 

  144. Dong Z., Ferger B., Feldon J., and Bueler H. (2002) Overexpression of Parkinson’s disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J. Neurobiol. 53, 1–10.

    PubMed  CAS  Google Scholar 

  145. Feany M.B. and Bender W.W. (2000) A Drosophila model of Parkinson’s disease. Nature 404, 394–398.

    PubMed  CAS  Google Scholar 

  146. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., and Bonini N.M. (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 295, 865–868.

    PubMed  CAS  Google Scholar 

  147. Auluck P.K. and Bonini N.M. (2002) Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 8, 1185–1186.

    PubMed  CAS  Google Scholar 

  148. Lakso M., Vartiainen S., Moilanen A.M., Sirvio J., Thomas J.H., Nass R., et al. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 86, 165–172.

    PubMed  CAS  Google Scholar 

  149. Rockenstein E., Hansen L.A., Mallory M., Trojanowski J.Q., Galasko D., and Masliah E. (2001) Altered expression of the synuclein family mRNA in Lewy body and Alzheimer’s disease. Brain Res. 914, 48–56.

    PubMed  CAS  Google Scholar 

  150. Markopoulou K., Wszolek Z.K., Pfeiffer R.F., and Chase B.A. (1999) Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. Ann. Neurol. 46, 374–381.

    PubMed  CAS  Google Scholar 

  151. Neystat M., Lynch T., Przedborski S., Kholodilov N., Rzhetskaya M., and Burke R.E. (1999) Alpha-synuclein expression in substantia nigra and cortex in Parkinson’s disease. Mov. Disord. 14, 417–422.

    PubMed  CAS  Google Scholar 

  152. Kobayashi H., Kruger R., Markopoulou K., Wszolek Z., Chase B., Taka H., et al. (2003) Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson’s disease. Brain 126, 32–42.

    PubMed  Google Scholar 

  153. Kholodilov N.G., Neystat M., Oo T.F., Lo S.E., Larsen K.E., Sulzer D., et al. (1999) Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J. Neurochem. 73, 2586–2599.

    PubMed  CAS  Google Scholar 

  154. Petersen K., Olesen O.F., and Mikkelsen J.D. (1999) Developmental expression of alphasynuclein in rat hippocampus and cerebral cortex. Neuroscience 91, 651–659.

    PubMed  CAS  Google Scholar 

  155. Kholodilov N.G., Oo T.F., and Burke R.E. (1999) Synuclein expression is decreased in rat substantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine. Neurosci. Lett. 275, 105–108.

    PubMed  CAS  Google Scholar 

  156. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., and Przedborski S. (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74, 721–729.

    PubMed  CAS  Google Scholar 

  157. Manning-Bog A.B., McCormack A.L., Purisai M.G., Bolin L.M., and Di Monte D.A. (2003) Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci. 23, 3095–3099.

    PubMed  CAS  Google Scholar 

  158. Stefanis L., Kholodilov N., Rideout H.J., Burke R.E., and Greene L.A. (2001) Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. J. Neurochem. 76, 1165–1176.

    PubMed  CAS  Google Scholar 

  159. Greene L.A. and Rein G. (1977) Release storage and uptake of catecholamines by a clonal cell line of nerve growth factor (NGF) responsive pheo-chromocytoma cells. Brain Res. 129, 247–263.

    PubMed  CAS  Google Scholar 

  160. Solano S.M., Miller D.W., Augood S.J., Young A.B., and Penney J.B. Jr. (2000) Expression of alpha-synuclein parkin and ubiquitin carboxyterminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson’s disease. Ann. Neurol. 47, 201–210.

    PubMed  CAS  Google Scholar 

  161. Leonard S., Luthman D., Logel J., Luthman J., Antle C., Freedman R., et al. (1993) Acidic and basic fibroblast growth factor mRNAs are increased in striatum following MPTP-induced dopamine neurofiber lesion: assay by quantitative PCR. Brain Res. Mol. Brain Res. 18, 275–284.

    PubMed  CAS  Google Scholar 

  162. Rufer M., Wirth S.B., Hofer A., Dermietzel R., Pastor A., Kettenmann H., et al. (1996) Regulation of connexin-43 GFAP and FGF-2 is not accompanied by changes in astroglial coupling in MPTP-lesioned FGF-2-treated parkinsonian mice. J. Neurosci. Res. 46, 606–617.

    PubMed  CAS  Google Scholar 

  163. Mash D.C., Ouyang Q., Pablo J., Basile M., Izenwasser S., Lieberman A., et al. (2003) Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. J. Neurosci. 23, 2564–2571.

    PubMed  CAS  Google Scholar 

  164. Canales J.J. and Graybiel A.M. (2000) A measure of striatal function predicts motor stereotypy. Nat. Neurosci. 3, 377–383.

    PubMed  CAS  Google Scholar 

  165. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., and Mouradian M.M. (1999) Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274, 33,855–33,858.

    CAS  Google Scholar 

  166. Liu Y., Fallon L., Lashuel H.A., Liu Z., and Lansbury P.T. Jr. (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease susceptibility. Cell 111, 209–218.

    PubMed  CAS  Google Scholar 

  167. Tofaris G.K., Layfield R., and Spillantini M.G. (2001) Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509, 22–26.

    PubMed  CAS  Google Scholar 

  168. Ancolio K., Alves da Costa C., Ueda K., and Checler F. (2000) Alpha-synuclein and the Parkinson’s disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett. 285, 79–82.

    PubMed  CAS  Google Scholar 

  169. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., and Rubinsztein D.C. (2003) Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25,009–25,013.

    CAS  Google Scholar 

  170. Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V.M., et al. (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 277, 49,071–49,076.

    CAS  Google Scholar 

  171. Tofaris G.K., Razzaq A., Ghetti B., Lilley K., and Spillantini M.G. (2003) Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278, 44,405–44,411.

    CAS  Google Scholar 

  172. Sampathu D.M., Giasson B.I., Pawlyk A.C., Trojanowski J.Q., and Lee V.M. (2003) Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am. J. Pathol. 163, 91–100.

    PubMed  CAS  Google Scholar 

  173. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., et al. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science 293, 263–269.

    PubMed  CAS  Google Scholar 

  174. Mishizen-Eberz A.J., Guttmann R.P., Giasson B.I., Day G.A. 3rd Hodara R., Ischiropoulos H., et al. (2003) Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 86, 836–847.

    PubMed  CAS  Google Scholar 

  175. Iwata A., Maruyama M., Akagi T., Hashikawa T., Kanazawa I., Tsuji S., et al. (2003) Alpha-synuclein degradation by serine protease neurosin: Implication for pathogenesis of synucleinopathies. Hum. Mol. Genet. 12, 2625–2635.

    PubMed  CAS  Google Scholar 

  176. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164–173

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurobiology Laboratory, Institute of Biomedical Research of the Academy of Athens, Greece

    Kostas Vekrellis & Leonidas Stefanis

  2. Department of Neurology, Columbia University, New York, NY

    Hardy J. Rideout & Leonidas Stefanis

Authors
  1. Kostas Vekrellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hardy J. Rideout
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leonidas Stefanis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonidas Stefanis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vekrellis, K., Rideout, H.J. & Stefanis, L. Neurobiology of α-synuclein. Mol Neurobiol 30, 1–21 (2004). https://doi.org/10.1385/MN:30:1:001

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MN:30:1:001

Index Entries

Search

Navigation